ELVN
Enliven Therapeutics, Inc.
Latest Form 4:Sale$293KbyCollins Helen Louise (CHIEF MEDICAL OFFICER) · filed Aug 19, 2026
Enliven Therapeutics, Inc. (ELVN) has 42 SEC Form 4 filings (96 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Aug 19, 2026.
The most active filer is CHIEF MEDICAL OFFICER Collins Helen Louise with 10 filings. Insiders have net sold $67.3M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Richard A. Fair
- Employees:61
- HQ:Boulder, CO, US
- IPO:2020-03-12
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$76.2M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$4.5B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| CHIEF MEDICAL OFFICER | Sale | 5,000 | $293K | Aug 19 | SEC ↗ | |
| CHIEF FINANCIAL OFFICER | Sale | 6,018 | $353K | Aug 19 | SEC ↗ | |
Derynck Mika KFirst filing | Director | Sale | 158,795 | $9.6M | Aug 7 | SEC ↗ |
| CHIEF FINANCIAL OFFICER | Sale | 6,018 | $317K | Jul 21 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 5,000 | $263K | Jul 21 | SEC ↗ | |
| Director | Sale | 10,000 | $505K | Jul 8 | SEC ↗ | |
| 10% Owner | Sale | 860,123 | $39.0M | Jun 24 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 5,000 | $219K | Jun 22 | SEC ↗ | |
Hohl BenjaminFirst in 3 months | CHIEF FINANCIAL OFFICER | Sale | 6,018 | $264K | Jun 22 | SEC ↗ |
| 10% Owner | Sale | 281,408 | $12.7M | Jun 17 | SEC ↗ | |
Kunkel Lori AnneFirst filing | Director | Sale | 10,000 | $345K | Jun 9 | SEC ↗ |
| CHIEF MEDICAL OFFICER | Sale | 5,000 | $199K | May 20 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 5,000 | $238K | Apr 21 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 40,000 | $1.4M | Mar 27 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 5,000 | $139K | Mar 19 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 29,871 | $897K | Mar 11 | SEC ↗ | |
| CHIEF MEDICAL OFFICER | Sale | 10,129 | $306K | Mar 11 | SEC ↗ | |
Hohl BenjaminFirst in 5 months | CHIEF FINANCIAL OFFICER | Sale | 10,000 | $296K | Mar 10 | SEC ↗ |
Collins Helen LouiseFirst filing | CHIEF MEDICAL OFFICER | Sale | 45,000 | $1.2M | Feb 19 | SEC ↗ |
| Director | Sale | 1,230 | $32K | Feb 19 | SEC ↗ | |
| CHIEF SCIENTIFIC OFFICER | Sale | 5,000 | $145K | Feb 10 | SEC ↗ | |
| Director | Sale | 1,230 | $33K | Jan 22 | SEC ↗ | |
| CHIEF SCIENTIFIC OFFICER | Sale | 20,000 | $535K | Jan 22 | SEC ↗ | |
| CHIEF OPERATING OFFICER | Sale | 48,300 | $1.4M | Jan 13 | SEC ↗ | |
Heyman Richard A.First filing | Director | Sale | 9,635 | $241K | Jan 12 | SEC ↗ |
Heyman Richard A.First filing | Director | Sale | 4,285 | $107K | Jan 12 | SEC ↗ |
| CHIEF SCIENTIFIC OFFICER | Sale | 41,302 | $993K | Jan 12 | SEC ↗ | |
| CHIEF SCIENTIFIC OFFICER | Sale | 91,198 | $2.5M | Jan 12 | SEC ↗ | |
| CHIEF SCIENTIFIC OFFICER | Sale | 5,000 | $84K | Dec 23 | SEC ↗ | |
| CHIEF OPERATING OFFICER | Sale | 6,663 | $140K | Dec 10 | SEC ↗ | |
| CHIEF SCIENTIFIC OFFICER | Sale | 12,500 | $279K | Nov 21 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 12,500 | $273K | Nov 19 | SEC ↗ | |
| CHIEF OPERATING OFFICER | Sale | 6,667 | $116K | Nov 12 | SEC ↗ | |
| CHIEF SCIENTIFIC OFFICER | Sale | 12,500 | $276K | Oct 22 | SEC ↗ | |
| PRESIDENT AND CEO | Sale | 12,500 | $267K | Oct 21 | SEC ↗ | |
Patel AnishFirst filing | CHIEF OPERATING OFFICER | Sale | 6,667 | $134K | Oct 9 | SEC ↗ |
Hohl BenjaminFirst filing | CHIEF FINANCIAL OFFICER | Sale | 3,250 | $66K | Oct 1 | SEC ↗ |
Lyssikatos Joseph PFirst filing | CHIEF SCIENTIFIC OFFICER | Sale | 4,000 | $81K | Sep 30 | SEC ↗ |
Kintz SamuelFirst filing | PRESIDENT AND CEO | Sale | 3,700 | $74K | Sep 30 | SEC ↗ |
Related companies
Enliven Therapeutics, Inc. is in the Healthcare sector.